These setbacks have highlighted the need to determine additional biomarkers that better predict the responses to Bosutinib, a task that has been partially achieved in prior trials by displaying positive responses in Src-expressing cancers with Bosutinib, dasatinib, and other small molecule inhibitors. Here, SRC is linked to cancer.